Shots:
- The P-II/III XIRIUS study involves assessing subretinal injection of cotoretigene toliparvovec in males with a genetically confirmed diagnosis of XLRP. Part 1 of the study was a 24mos. dose-escalation study while part II was a 12mos. dose expansion study with a high & low dose selected from part I based on a benefit/risk assessment
- The study failed to meet its 1EPs demonstrating improvement in the proportion of treated study eyes with ≥7 dB improvement from baseline at ≥5 of the 16 central loci of the 10-2 grid assessed by MAIA microperimetry
- BIIB112 is an investigational AAV8 vector-based gene therapy to provide full-length functioning RPGR protein in patients with XLRP
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Stat News
The post Biogen’s BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP first appeared on PharmaShots.
